Scientists have long tinkered with cell-free methods of protein synthesis, but turning their lab bench discoveries into commercially actionable ones is usually a tedious affair that ultimately requires the return to traditional cell line development. Sutro Biopharma claims to have developed a speedy cell-free way of producing proteins that can swiftly shift from laboratory to commercial scale. Rather than packaging the process for widespread use by researchers, Sutro is seeking to collaborate with partners intent on creating biopharmaceuticals--ideally, companies interested in high-throughput protein engineering.
310 Utah Avenue
Suite 150
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
The updated US FDA label modifies dose titration based on TRAILBLAZER-ALZ 6, a study that showed a more gradual rise in dosing levels reduced ARIA-E incidence without reducing amyloid clearance.
Joshi joins the parent company of Citeline, which houses flagship publications Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.